OneDigital Investment Advisors LLC Acquires 3,097 Shares of ChromaDex Co. (NASDAQ:CDXC)

OneDigital Investment Advisors LLC raised its position in ChromaDex Co. (NASDAQ:CDXC) by 5.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,414 shares of the company’s stock after buying an additional 3,097 shares during the quarter. OneDigital Investment Advisors LLC owned about 0.08% of ChromaDex worth $217,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CDXC. WINTON GROUP Ltd acquired a new stake in shares of ChromaDex during the 2nd quarter valued at $597,000. Bank of New York Mellon Corp lifted its position in shares of ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after acquiring an additional 119,915 shares during the period. BSW Wealth Partners bought a new position in shares of ChromaDex during the 3rd quarter worth about $324,000. Rhumbline Advisers bought a new stake in shares of ChromaDex during the second quarter valued at approximately $124,000. Finally, Perritt Capital Management Inc. bought a new position in shares of ChromaDex in the first quarter valued at $139,000. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Trading Down 2.5 %

Shares of NASDAQ CDXC opened at $7.44 on Friday. The stock has a market cap of $568.29 million, a price-to-earnings ratio of 743.00 and a beta of 1.88. ChromaDex Co. has a 1-year low of $1.32 and a 1-year high of $7.85. The stock’s 50-day moving average is $4.53 and its 200 day moving average is $3.56.

ChromaDex (NASDAQ:CDXC) last issued its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The company had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. During the same period in the prior year, the business posted ($0.01) EPS. On average, analysts forecast that ChromaDex Co. will post 0.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CDXC shares. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th. Roth Mkm increased their target price on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright increased their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.